LAUSR

agreements and/or contracts with the Vectura Group should be discontinued at the earliest possible opportunity. Further-more, we are calling on all companies to publicly communicate their current arrangements with the Vectura group and to actively develop, implement and communicate their strat-egies to exit these agreements. Second, patient welfare should be at the centre of decisions about inhaler prescribing. Educational resources from professional respiratory societies and patient advocacy groups are needed to support prescribers and patients, respectively, to make informed decisions that do not result in poor lung health outcomes. The potential for stigmatizing patients and making them feel guilty about their choice of inhaler should be avoided at all costs. Some patients and prescribers will elect to continue using inhalers linked to Vectura. In some situations, there will be no suitable alternative. Others may want to switch to an inhaler with no links to Vectura, where there is a suitable alternative option. including restrictions nicotine